EC OKs label extension for BMS's Orencia
This article was originally published in Scrip
Executive Summary
The European Commission has approved an expanded indication for Bristol-Myers Squibb's Orencia (abatacept) for use in combination with methotrexate for moderate-to-severe active rheumatoid arthritis (RA) in patients who have responded inadequately to previous therapy with one or more disease-modifying antirheumatic drugs (DMARDs) including methotrexate or a TNF-alpha inhibitor.